Zura Bio — Third Quarter 2026 Earnings Summary

Zura Bio reported third-quarter 2026 financial results showing a net loss of $25.8 million, or $0.20 per share, with total operating expenses reaching $28.8 million. The company holds $187.7 million in cash and cash equivalents as of September 30, 2026, which is projected to fund operations through the end of 2028. Clinical progress includes the completion of enrollment for the TibuSHIELD study in hidradenitis suppurativa and the TibuSURE study in systemic sclerosis, with topline data expected in late 2026 and early 2027 respectively. Additionally, the NEXUS-PMR Phase 2 study for polymyalgia rheumatica has received FDA clearance and is scheduled to initiate by the end of 2026.